Results 11 to 20 of about 1,211,683 (168)

The Potential to Reduce Patient Co-Payment and the Public Payer Spending in Poland through an Optimised Implementation of the Generic Substitution: The Win-Win Scenario Suggested by the Real-World Big Data Analysis

Pharmaceutics, 2021
High medication costs are one of the major barriers to patient adherence. Medication affordability might be improved by generic substitution. The aim of this study was to assess the effectiveness of the implementation of generic substitution mechanisms ...
Przemysław Kardas, Aneta Lichwierowicz, Filip Urbański, Beata Szadkowska-Opasiak, Ewa Karasiewicz, Paweł Lewek, Dominika Krupa, Marcin Czech   +7 more
doaj   +1 more source

Willingness to pay for treatment with highly active antiretroviral (HAART) drugs: a rural case study in Cameroon

SAHARA-J, 2004
This paper reports on the willingness of HIV/AIDS patients to pay for the most affordable triple therapy combination of antiretrovirals in a local setting in Cameroon.
Kenneth Ngwambokong Muko, Valentine Che Ngwa, Leslie Chigang, Igbinosum Gladys Ngwa, Anke Meiburg, Elvis Neba Shu   +5 more
doaj   +1 more source

The effects of subcurative praziquantel treatment on life-history traits and trade-offs in drug-resistant Schistosoma mansoni [PDF]

, 2016
Natural selection acts on all organisms, including parasites, to maximise reproductive fitness. Drug resistance traits are often associated with life-history costs in the absence of treatment.
Viana, Mafalda, Faust, Christina L., Haydon, Dan T., Webster, Joanne P., Lamberton, Poppy H.L.   +4 more
core   +9 more sources

Value‐based pricing: Toward achieving a balance between individual and population gains in health benefits

Cancer Medicine, 2020
Objectives Value‐based pricing of oncology drugs provides a best estimate for the price of a drug, as it relates to the benefits it provides for individual patients. To date, the impact of value‐based pricing to reference cost‐effectiveness thresholds (λ)
Ambica Parmar, Tina Jiao, Ronak Saluja, Kelvin K. W. Chan   +3 more
doaj   +1 more source

Direct healthcare costs and their relationships with age at start of drug use and current pattern of use: a cross-sectional study

São Paulo Medical Journal, 2021
BACKGROUND: It is well known that early start of drug use can lead users to psychosocial problems in adulthood, but its relationship with users’ direct healthcare costs has not been well established OBJECTIVES: To estimate the direct healthcare costs ...
Paula Becker, Denise Razzouk
doaj   +1 more source

Antiparasitic Drugs in the United States—Two Roads to High Prices

Frontiers in Sociology, 2020
High prescription drug prices contribute significantly to healthcare spending in the United States and compromise patients' access to quality medical care.
Arman A. Shahriar, Jonathan D. Alpern, Jonathan D. Alpern   +2 more
doaj   +1 more source

Decision-making on listing new medicines for public funding in New Zealand: the case of 'new' type 2 diabetes medications [PDF]

Journal of Primary Health Care, 2022
IntroductionNew medicines for the management of type 2 diabetes became available internationally in 2005, yet only in 2018 did the first of these become available in New Zealand.
Caroline Stretton, Charon Lessing, Farzana Sarkisova   +2 more
doaj  

Costs of orphan medicinal products: longitudinal analysis of expenditure in Wales

Orphanet Journal of Rare Diseases, 2023
Background The Orphan Regulation ((EC) No 141/2000) has successfully redirected private and public investment towards previously neglected areas through incentives, regulatory obligations and rewards.
Yankier Pijeira Perez, Eifiona Wood, Dyfrig A Hughes   +2 more
doaj   +1 more source

DTI-SNNFRA: Drug-Target interaction prediction by shared nearest neighbors and fuzzy-rough approximation [PDF]

PLOS ONE 16(2): e0246920. (2021) 1-19, 2020
In-silico prediction of repurposable drugs is an effective drug discovery strategy that supplements de-nevo drug discovery from scratch. Reduced development time, less cost and absence of severe side effects are significant advantages of using drug repositioning.
arxiv   +1 more source

Costs of Parkinson's Disease and Antiparkinsonian Pharmacotherapy: An Italian Cohort Study [PDF]

, 2010
Objective: Antiparkinsonian pharmacotherapy is costly and the determinants of drug costs in Parkinson's disease (PD) have been poorly investigated. The objective of this study was to investigate the costs of PD and antiparkinsonian drugs in an Italian ...
Balzer-Geldsetzer, Monika, Barone, Paolo, Bötzel, Kai, Campenhausen, Sonja von, Dodel, Richard, Eggert, Karla, Longo, Katia, Oertel, Wolfgang H., Reese, Jens P., Spiga, Giuseppe, Winter, Yaroslav   +10 more
core   +1 more source